60 Degrees Pharmaceuticals’ (SXTP) “Sell (E+)” Rating Reaffirmed at Weiss Ratings

Weiss Ratings reaffirmed their sell (e+) rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) in a research note issued to investors on Wednesday morning,Weiss Ratings reports.

Separately, HC Wainwright restated a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a report on Friday, January 10th.

60 Degrees Pharmaceuticals Stock Up 1.5 %

60 Degrees Pharmaceuticals stock opened at $0.53 on Wednesday. 60 Degrees Pharmaceuticals has a 52 week low of $0.45 and a 52 week high of $7.20. The firm’s 50-day simple moving average is $0.99 and its 200 day simple moving average is $1.09. The firm has a market capitalization of $3.11 million, a PE ratio of -0.05 and a beta of 4.22.

Insider Buying and Selling

In other news, CEO Geoffrey S. Dow acquired 35,823 shares of the stock in a transaction on Monday, December 9th. The stock was bought at an average price of $1.27 per share, with a total value of $45,495.21. Following the completion of the transaction, the chief executive officer now directly owns 94,580 shares of the company’s stock, valued at $120,116.60. The trade was a 60.97 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last quarter, insiders acquired 60,372 shares of company stock valued at $76,975. 10.27% of the stock is currently owned by corporate insiders.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.